To that end, he used two methods to activate the adaptive thermogenic capacity in mice: long-term cold acclimatization and a chronic administration of a β3-AR agonist. He demonstrated that activation of the beta-adrenergic system either with long-term cold acclimation or pharmacological β3-AR activation prevented the onset of glucocorticoid-induced adipose dysfunction and related metabolic comorbidities. Thus, targeting β3-AR may be regarded as a potential therapeutic strategy to prevent glucocorticoid-induced metabolic disease.
Manuel will continue working as a postdoc in Holger Henneicke’s lab focusing on the interaction between glucocorticoids and IL4 in skeletal biology at the CRTD in Dresden.
Keep up the good work, Manuel!